Accelerating the expansion of what we know about COVID-19 is critical to conquering the pandemic. The world needs faster testing, faster vaccine development, faster results — but how?
The scientific and medical research communities stand united in their steadfast efforts to find not just a vaccine, but other effective therapeutics such as antiviral drugs, peptide inhibitors, nucleoside analogues, and monoclonal antibodies. We have never been more honored to stand with them.
Several short months ago, finding ourselves in the current pandemic situation would have been almost unthinkable. Since the advent of antibiotics in the mid-19th century provided the ability to cure nearly any bacterial infection, as well as breakthrough vaccination approaches against diphtheria or tetanus, life-threatening diseases have shifted from bacterial and viral causes to mutated human cells, (e.g., cancer).
Throughout the response to the COVID-19 pandemic, clinicians and researchers have faced daunting questions of how to scale testing in order to meet the demand. Research laboratories that may have been accustomed to processing a few handfuls of samples a day are now being asked to process thousands as they seek solutions to this crisis.
Agilent’s legacy is largely built on the high-quality instruments we produce, which are found in labs around the world. However, the urgent need for COVID-19 testing has led to a surge in demand for one of our lesser-known products: magnetic beads.
In this article, we present a quick summary of journal articles published by various authors on small-molecule drugs that are being repurposed for COVID-19 treatment in clinical trials around the world.
This year has thrown the world a curve ball, and it’s causing many in management positions to reassess their ability to respond to unforeseen changes. The current pandemic is still full of uncertainty. What can we do to prepare for whatever comes?
At the time of writing, there are no vaccines or therapies available for the prevention or cure of COVID-19. Many promising avenues are being investigated, including the use of mAbs as a blocking agent to neutralize the SARS-CoV-2 virus.
Structural Genomics Consortium (SGC) at Oxford University and Agilent collaborate to help develop robust and reliable methods to analyze SARS-CoV-2 spike proteins.
In this article, we look at examples from each vaccine class where chromatographic separations have helped in the characterization of vaccines.
COVID-19 seems not to discriminate, affecting people of all ages, races, and genders across the globe. But the degree to which each person reacts to the intrusion of the virus has varied drastically.
As the response to the COVID-19 pandemic continues, officials and researchers have made a concentrated push to ramp up testing efforts. Testing not only helps inform us of the virus' prevalence but can also give us insight into how the virus has spread and whether it has accumulated potentially relevant mutations.
Collaborations within the greater virology community, including academic institutions, are accelerating the development of an antibody discovery program and get it into the clinic
Identifying and linking viral mutations to observations in geographic origin, infectivity, and symptoms is helping researchers model how the virus has spread and how it may behave.
Tufts University's Graduate School of Biomedical Sciences, using BioTek (now a part of Agilent) instruments, seeks to understand the immune system response when facing a threat like the novel coronavirus.
Faster results and faster action are needed to help prevent the spread of COVID-19. See how laboratories are reducing time it takes for results from days to hours.
As the race to overcome the COVID-19 pandemic continues, scientists working together have already made inroads not only on vaccine development efforts, but also on the ongoing impact of the novel coronavirus.
At Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL), microbiologists, virologists, and other scientists have dropped their routine research projects to focus on the critical search for vaccines and treatments for COVID-19.
For Research Use Only. Not for use in diagnostic procedures.
Disclaimer: Agilent products are NOT approved for COVID-19 testing, diagnosis, treatment, or mitigation. Agilent has not validated a product to detect the novel coronavirus.